CAS:PRO's ROA % is ranked better than 61.63% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.685
vs CAS:PRO: 4.92
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ROA % Related Terms
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ROA % Chart
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ROA % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) has a ROA % of 5.39% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. This is 50% below median its historical median of 10.72. Over the past decade, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's ROA % has ranged from 4.92 to 14.71. According to the industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #386 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 38.4%.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's ROA % too high?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current ROA % of 5.39% is 50% below median its 10-year median of 10.72. Over the past 10 years, this metric has ranged from a low of 4.92 to a high of 14.71. The Drug Manufacturers industry median ROA % is 2.69. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's value of 5.39% is 100.7% above this industry median. Based on the distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #386 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #386 out of 1006 companies for ROA %. This puts PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM in the upper half of its industry. The industry median ROA % is 2.69. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's value of 5.39% is 100.7% above this benchmark. Historically, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's own ROA % has ranged from 4.92 to 14.71 over the past decade. While the company's 10-year median is 10.72 vs. the industry median of 2.69, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current ROA % of 5.39% is 100.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current ROA % is 5.39%, which is 50% below median its own 10-year median of 10.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock overvalued right now?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) is currently considered Fairly Valued. The stock's GF Value™ is MAD1,328.12, compared to a current price of MAD1,349.00 — trading 1.6% above its estimated fair value. The current ROA % is 5.39%, which is 50% below median its 10-year median of 10.72 and 100.7% above the Drug Manufacturers industry median of 2.69. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO), the current ROA % is 5.39% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Overvalued in 2026?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock appears to be overvalued.
The current stock price of MAD1,349.00 is trading 1.6% above its estimated GF Value™ of MAD1,328.12.
GuruFocus considers PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM to be Fairly Valued.
Key valuation signals for CAS:PRO:
ROA %: 5.39% (50% below median its 10-year median of 10.72)
GF Value™: MAD1,328.12 vs. price of MAD1,349.00 (1.6% above fair value)
Industry Position: 100.7% above the Drug Manufacturers median (#386 of 1006)
No single metric tells the full story. See the CAS:PRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Business Description
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.
84GF Score
Get the complete analysis for CAS:PRO
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:PRO has been successfully added to your 
